Literature DB >> 2501242

Repeat megavoltage irradiation of pituitary and suprasellar tumors.

J C Flickinger1, M Deutsch, L D Lunsford.   

Abstract

From 1965 to 1984, ten patients with suprasellar or pituitary tumors received repeat courses of radiation therapy at the Joint Radiation Oncology Center of the University of Pittsburgh. The radiation doses varied between 36.00 to 53.65 Gy for the first treatment course and from 35.00 to 49.60 Gy for retreatment. Six patients were treated for pituitary tumors, two for germinoma, one for optic glioma, and one for craniopharyngioma. One died of disease progression 19 years after a second course of radiation. Two patients were dead of intercurrent disease 0.2 and 1.5 years after repeat radiation. The remainder are free of disease progression 1.6 to 20.5 years after repeat irradiation. Optic neuropathy developed in one patient 1.3 years following a second course of treatment to 40 Gy in 20 fractions administered 7.5 years after initial treatment to 46 Gy in 23 fractions. Neither the Nominal Standard Dose nor the Neuret formula provided an adequate estimate of the repair of radiation. An estimation that 40% of the original radiation dose effect is still present appears to be a reasonable "rule of thumb" guideline to account for prior radiotherapy.

Entities:  

Mesh:

Year:  1989        PMID: 2501242     DOI: 10.1016/0360-3016(89)90385-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Reirradiation for recurrent cerebral astrocytoma.

Authors:  D L Silbergeld; B R Griffin; G A Ojemann
Journal:  J Neurooncol       Date:  1992-02       Impact factor: 4.130

Review 2.  Updates in outcomes of stereotactic radiation therapy in acromegaly.

Authors:  Monica Livia Gheorghiu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

3.  The incidence of cerebrovascular accidents and second brain tumors in patients with pituitary adenoma: a population-based study.

Authors:  Paul D Brown; Miran Blanchard; Krishan Jethwa; Kelly D Flemming; Cerise A Brown; Robert W Kline; Debra J Jacobson; Jennifer St Sauver; Bruce E Pollock; Yolanda I Garces; Scott L Stafford; Michael J Link; Dana Erickson; Robert L Foote; Nadia N I Laack
Journal:  Neurooncol Pract       Date:  2014-03

Review 4.  Treatment of pituitary tumors: radiation.

Authors:  Agnes Mondok; György T Szeifert; Arpád Mayer; Sándor Czirják; Edit Gláz; István Nyáry; Károly Rácz
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

Review 5.  STEREOTACTIC RADIATION THERAPY IN PITUITARY ADENOMAS, IS IT BETTER THAN CONVENTIONAL RADIATION THERAPY?

Authors:  M L Gheorghiu; M Fleseriu
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Oct-Dec       Impact factor: 0.877

6.  Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma.

Authors:  Michael E Sughrue; Isaac Yang; Ari J Kane; Shanna Fang; Aaron J Clark; Derrick Aranda; Igor J Barani; Andrew T Parsa
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

7.  A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG).

Authors:  Maurizio Amichetti; Dante Amelio
Journal:  Cancers (Basel)       Date:  2011-10-28       Impact factor: 6.639

8.  Long-term safety of gamma knife radiosurgery (SRS) for acromegaly.

Authors:  Hugh P Sims-Williams; Kaveesha Rajapaksa; John Yianni; Lee Walton; Saurabh Sinha; Matthias Radatz; Esther Herbert; Mike Bradburn; John Newell-Price
Journal:  Pituitary       Date:  2021-05-26       Impact factor: 4.107

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.